

PATIENT DATA FOR PROSPECTIVE PROSTATE CANCER STUDY

AGE	INITIAL PSA	FOLLOW-UP PSA	% PSA DECREASE	TIME WITH DISEASE	GLEASON SCORE	CLINICAL STAGE	BIOPSY STAGE	IPSS-INDEX	IPSS CHANGE	EPS	EPS CHANGE
61	8.5 ng/ml	3.1 ng/ml	64%	72 months	5 (3+2)	T2c	T2c	5.5-2.5 = 3	55%	256-113	56%
68	7.0 ng/ml	2.4 ng/ml	66%	62 months	5 (3+2)	T1c	T2a	19.5-8.5 = 11	56%	85-15	82%
43	5.4 ng/ml	2.1 ng/ml	61%	41 months	6 (3+3)	T1c	T2a	4-0 = 0	100%	325-60	82%
65	11.7 ng/ml	5.8 ng/ml	50%	60 months	5(3+2)/6(3+3)	T1c	T2b				
64	4.7 ng/ml	1.7 ng/ml	64%	72 months	6 (3+3)	T1c	T2a				
55	2.1 ng/ml	2.8 ng/ml	+33%	42 months	5 (3+2)	T2c	T2c	6.5-2 = 4.5	69%	350-158	55%
56	7.3 ng/ml	4.5 ng/ml	38%	40 months	5(2+3)/6(3+3)	T2a	T2b	10.5-6 = 4.5	43%	TNTC-5	99%
70	6.9 ng/ml	5.1 ng/ml	26%	19 months	6 (3+3)	T2c	T2a	11.5-7.5 = 4	35%	268-17	94%
68	6.9 ng/ml	6.0 ng/ml	13%	38 months	6 (3+3)	T1c	T2a	4-0 = 0	100%		
56	9.1 ng/ml	5.5 ng/ml	40%	58 months	6 (3+3)	T1c	T2a	11-7 = 4	36%	375-150	60%
61	3.0 ng/ml	0.8 ng/ml	73%	24 months	5 (3+2)	T1c	T2a				
48	3.2 ng/ml	2.0 ng/ml	38%	21 months	6 (3+3)	T2a	T2b	9.5-2 = 7.5	79%	278-40	86%
69	6.2 ng/ml	4.1 ng/ml	34%	84 months	5 (3+2)	T1c	T1a	15.5-10 = 5.5	35%	205-9	96%
56	4.4 ng/ml	1.7 ng/ml	61%	39 months	6(3+3)/7(3+4)	T2c	T2c	8.5-1.5 = 7	82%	350-30	91%
74	11.4 ng/ml	12.3 ng/ml	+8%	34 months	6 (3+3)	T2b	T2b				
63	6.8 ng/ml	1.7 ng/ml	75%	49 months	5 (3+2)	T1c	T2a	5.5-2.5 = 3	55%	275-70	75%
71	6.6 ng/ml	1.8 ng/ml	73%	24 months	6 (3+3)	T1c	T2c	7.5-6 = 1.5	20%	185-35	81%
64	14.4 ng/ml	1.5 ng/ml	90%	29 months	6 (3+3)	T1c	T2a				
70	8.4 ng/ml	1.8 ng/ml	79%	18 months	6 (3+3)	T1c	T2a				
72	4.4 ng/ml	4.7 ng/ml	+7%	14 months	6(3+3)/7(3+4)	T2b	T2c				
55	4.1 ng/ml	1.6 ng/ml	61%	15 months	6(3+3)	T1c	T2c	2.5-0 = 0	100%	210-10	95%
72	6.1 ng/ml	1.3 ng/ml	79%	13 months	5(3+2)/6(3+3)	T1c	T2c				
71	8.6 ng/ml	2.9 ng/ml	66%	17 months	7(4+3)	T1c	T2a	14.5-7 = 7.5	52%	300-200	33%
TOTALS:	157.2 ng/ml	77.2 ng/ml	802	885							
	Mean	Mean PSA	Mean %	Mean					Mean %		Mean %
	Starting PSA	Change	Decrease	Months					Change		Change
	6.8 ng/ml	3.4 ng/ml	50%	38.5					61%		77.5%

EPS=Expressed Prostatic Secretion (An Indication of Prostate Inflammation)

PSA=Prostate Specific Antigen

IPSS-Index=International Prostate Symptom Score

TNTC=Too Numerous to Count

Gleason Score: 2-10 (Primary Cancer Grade + Secondary Cancer Grade) with 2 being the most favorable and 10 being the worst

Ronald E. Wheeler, M.D.
August 2005